European stocks were also tepid. The moves came after UK GDP data showed growth slowed to 0.1% in the third quarter.

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...